By Katherine Hamilton
Pacira Biosciences has authorized a share buyback program of up to $300 million.
The developer of non-opioid pain relievers said Thursday the repurchase program replaces a previous $150 million buyback plan authorized in May 2024.
The new plan expires at the end of December 2026, Pacira said.
"This increased share repurchase authorization underscores the board's confidence in Pacira's growth strategy and our commitment to delivering value to shareholders," Chief Executive Frank Lee said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
April 17, 2025 17:24 ET (21:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。